Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Immutep Limited
NASDAQ:IMMP
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +209.4% | +76.1% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +209.4% over three years. Forward estimates point to Revenue at +76.1% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Candel Therapeutics, Inc. NASDAQ:CADL | $772.63M | $10.55 | Not rated | -9.2 | +16.88% |
Achieve Life Sciences, Inc. NASDAQ:ACHV | $724.77M | $7.06 | Not rated | -5.1 | +56.58% |
Allogene Therapeutics, Inc. NASDAQ:ALLO | $614.38M | $1.78 | Not rated | -2.7 | -43.20% |
Capricor Therapeutics, Inc. NASDAQ:CAPR | $481.36M | $8.37 | Not rated | -13.9 | +49.11% |
Cabaletta Bio, Inc. NASDAQ:CABA | $445.14M | $2.73 | Not rated | -1.8 | -56.41% |
Editas Medicine, Inc. NASDAQ:EDIT | $414.35M | $2.70 | Not rated | -2.4 | -30.34% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $306.09M | $5.09 | Not rated | -1.4 | -28.79% |
Entrada Therapeutics, Inc. NASDAQ:TRDA | $263.98M | $6.80 | Not rated | -1.7 | -43.76% |
ProQR Therapeutics N.V. NASDAQ:PRQR | $195.87M | $1.86 | Not rated | -3.8 | -44.71% |
Mereo BioPharma Group plc NASDAQ:MREO | $44.69M | $0.28 | Not rated | -1.4 | -82.42% |
Continue the stock analysis
Jump to another research area for this company.